ZA200709608B - Histone deacetylase inhibitors - Google Patents
Histone deacetylase inhibitorsInfo
- Publication number
- ZA200709608B ZA200709608B ZA200709608A ZA200709608A ZA200709608B ZA 200709608 B ZA200709608 B ZA 200709608B ZA 200709608 A ZA200709608 A ZA 200709608A ZA 200709608 A ZA200709608 A ZA 200709608A ZA 200709608 B ZA200709608 B ZA 200709608B
- Authority
- ZA
- South Africa
- Prior art keywords
- histone deacetylase
- deacetylase inhibitors
- linker1
- linker2
- linked
- Prior art date
Links
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title abstract 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 title abstract 2
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000165 tricyclic carbocycle group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0510204.1A GB0510204D0 (en) | 2005-05-19 | 2005-05-19 | Enzyme inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200709608B true ZA200709608B (en) | 2008-12-31 |
Family
ID=34708420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200709608A ZA200709608B (en) | 2005-05-19 | 2007-11-07 | Histone deacetylase inhibitors |
Country Status (20)
Country | Link |
---|---|
US (1) | US7932246B2 (es) |
EP (1) | EP1881977B1 (es) |
JP (1) | JP4954200B2 (es) |
KR (1) | KR20080016539A (es) |
CN (1) | CN101163696B (es) |
AT (1) | ATE494283T1 (es) |
AU (1) | AU2006248788B2 (es) |
BR (1) | BRPI0611522B1 (es) |
CA (1) | CA2605050C (es) |
DE (1) | DE602006019410D1 (es) |
DK (1) | DK1881977T3 (es) |
ES (1) | ES2358604T3 (es) |
GB (2) | GB0510204D0 (es) |
IL (1) | IL186362A (es) |
MX (1) | MX2007013066A (es) |
NZ (1) | NZ562519A (es) |
PL (1) | PL1881977T3 (es) |
PT (1) | PT1881977E (es) |
WO (1) | WO2006123121A1 (es) |
ZA (1) | ZA200709608B (es) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008029349A2 (en) * | 2006-09-04 | 2008-03-13 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
GB0619753D0 (en) * | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
JP5583406B2 (ja) | 2006-10-28 | 2014-09-03 | メチルジーン インコーポレイテッド | ヒストンデアセチラーゼの阻害剤 |
BRPI0622100A2 (pt) | 2006-10-30 | 2011-12-27 | Chroma Therapeutics Ltd | hidroxamatos como inibidores de desacetilase de histona |
US20100022514A1 (en) * | 2006-12-15 | 2010-01-28 | Norvartis Ag | Heterocycle Compounds and Methods of Use Thereof |
KR20100095430A (ko) | 2007-11-02 | 2010-08-30 | 메틸진 인크. | 히스톤 탈아세틸화효소의 저해물질 |
CA2709383A1 (en) | 2007-12-14 | 2009-06-25 | Milton L. Brown | Histone deacetylase inhibitors |
GB0803747D0 (en) | 2008-02-29 | 2008-04-09 | Martin | Enzyme and receptor modulation |
DK2274301T3 (da) | 2008-03-27 | 2013-01-02 | Janssen Pharmaceutica Nv | Azabicyclohexylsubstituerede indolylalkylaminoderivater som hidtil ukendte inhibitorer af histondeacetylase |
EP2110377A1 (en) * | 2008-04-15 | 2009-10-21 | DAC S.r.l. | Spirocyclic derivatives as histone deacetylase inhibitors |
WO2009137503A1 (en) * | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Hdac inhibitors and uses thereof |
WO2009137499A1 (en) * | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Inhibitors of histone deacetylase |
EP2285376A4 (en) * | 2008-05-16 | 2011-07-20 | Chipscreen Biosciences Ltd | 6-AMINONICOTINAMIDE DERIVATIVES FORMING POWERFUL AND SELECTIVE HISTONE DEACETYLASE INHIBITORS |
FR2945533B1 (fr) * | 2009-05-12 | 2011-05-27 | Sanofi Aventis | Derives de cyclopenta°c!pyrrolyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
EP2491038B1 (en) | 2009-10-23 | 2016-04-06 | Janssen Pharmaceutica N.V. | Disubstituted octahy - dropyrrolo [3,4-c]pyrroles as orexin receptor modulators |
JP5847087B2 (ja) | 2009-10-23 | 2016-01-20 | ヤンセン ファーマシューティカ エヌ.ベー. | オレキシン受容体調節因子としての縮合複素環式化合物 |
JP5848251B2 (ja) | 2009-10-23 | 2016-01-27 | ヤンセン ファーマシューティカ エヌ.ベー. | オレキシン受容体調節因子としての縮合複素環式化合物 |
WO2011113013A2 (en) | 2010-03-11 | 2011-09-15 | Hemaquest Pharmaceuticals, Inc. | Methods and compositions for treating viral or virally-induced conditions |
EP2621902B1 (en) | 2010-09-28 | 2017-04-12 | Panacea Biotec Ltd | 3-azabicyclo[3.1.0]hexane compounds useful for the treatment of cns disorders |
SG190211A1 (en) * | 2010-11-16 | 2013-06-28 | Acetylon Pharmaceuticals Inc | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
US9586962B2 (en) * | 2011-04-20 | 2017-03-07 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
GB201211310D0 (en) | 2012-06-26 | 2012-08-08 | Chroma Therapeutics Ltd | CSF-1R kinase inhibitors |
US9682966B2 (en) | 2012-08-16 | 2017-06-20 | The Scripps Research Institute | Kappa opioid ligands |
SI3222616T1 (sl) | 2012-10-17 | 2019-10-30 | Macrophage Pharma Ltd | N-(2-(4-(6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2H)-IL)-3,5- difluorofenil)etil)-L-alanin in njegov terbutil ester |
JP6626437B2 (ja) | 2013-10-08 | 2019-12-25 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | ヒストンデアセチラーゼ阻害剤とHer2阻害剤またはPI3K阻害剤のいずれかの組み合わせ |
EP3055299B1 (en) | 2013-10-10 | 2021-01-06 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors |
WO2015061684A1 (en) | 2013-10-24 | 2015-04-30 | Mayo Foundation For Medical Education And Research | Treatment of polycystic diseases with an hdac6 inhibitor |
CR20160308A (es) | 2013-12-03 | 2016-11-08 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores |
US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
WO2015187542A1 (en) * | 2014-06-02 | 2015-12-10 | Chdi Foundation Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
EP3166603B1 (en) | 2014-07-07 | 2020-02-12 | Acetylon Pharmaceuticals, Inc. | Treatment of leukemia with histone deacetylase inhibitors |
WO2016086060A1 (en) | 2014-11-26 | 2016-06-02 | The J. David Gladstone Institutes | Methods for treating a cytomegalovirus infection |
EP3226903A1 (en) | 2014-12-05 | 2017-10-11 | University of Modena and Reggio Emila | Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma |
TWI770525B (zh) | 2014-12-30 | 2022-07-11 | 美商瓦洛健康公司 | 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶 |
MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
JP2018504432A (ja) | 2015-02-05 | 2018-02-15 | フォーマ セラピューティクス,インコーポレイテッド | ユビキチン特異的プロテアーゼ7阻害物質としてのイソチアゾロピリミジノン、ピラゾロピリミジノン及びピロロピリミジノン |
WO2016126926A1 (en) | 2015-02-05 | 2016-08-11 | Forma Therapeutics, Inc. | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
WO2016126929A1 (en) | 2015-02-05 | 2016-08-11 | Forma Therapeutics, Inc. | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors |
MX2017011778A (es) * | 2015-03-13 | 2017-12-04 | Forma Therapeutics Inc | Compuestos y composiciones de alfa-cinamida como inhibidores de histona desacetilasa 8 (hdac8). |
US10272084B2 (en) | 2015-06-01 | 2019-04-30 | Regenacy Pharmaceuticals, Llc | Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy |
CA2960253A1 (en) | 2016-03-10 | 2017-09-10 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
WO2017184774A1 (en) | 2016-04-19 | 2017-10-26 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors, alone or in combination with btk inhibitors, for treating chronic lymphocytic leukemia |
WO2018013962A1 (en) * | 2016-07-15 | 2018-01-18 | Viracta Therapeutics, Inc. | Histone deacetylase inhibitors for use in immunotherapy |
KR102296703B1 (ko) | 2017-03-20 | 2021-09-01 | 포르마 세라퓨틱스 인크. | 피루베이트 키나제 (pkr) 활성화제로서의 피롤로피롤 조성물 |
GB201713975D0 (en) | 2017-08-31 | 2017-10-18 | Macrophage Pharma Ltd | Medical use |
WO2019057123A1 (zh) * | 2017-09-20 | 2019-03-28 | 杭州英创医药科技有限公司 | 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物 |
AU2018351651B2 (en) | 2017-10-20 | 2023-01-05 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
WO2019089676A1 (en) | 2017-10-31 | 2019-05-09 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
US11414406B2 (en) | 2018-02-02 | 2022-08-16 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
US20230055923A1 (en) | 2018-09-19 | 2023-02-23 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
BR112021005188A2 (pt) | 2018-09-19 | 2021-06-08 | Forma Therapeutics, Inc. | tratamento de anemia falciforme com um composto de ativação de piruvato cinase r |
US20220154282A1 (en) | 2019-03-12 | 2022-05-19 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
CN109810108B (zh) * | 2019-03-20 | 2021-08-06 | 华东理工大学 | 2,8-二氮杂-螺-[4,5]-癸烷类嘧啶-异羟肟酸化合物及其用途 |
CN109912576B (zh) * | 2019-03-20 | 2021-11-19 | 华东理工大学 | 环状或螺环二胺类嘧啶-异羟肟酸及其用途 |
JP2022534426A (ja) | 2019-05-31 | 2022-07-29 | イケナ オンコロジー, インコーポレイテッド | Tead阻害剤およびその使用 |
CN114502540A (zh) | 2019-05-31 | 2022-05-13 | 医肯纳肿瘤学公司 | Tead抑制剂和其用途 |
EP3976198A4 (en) | 2019-05-31 | 2023-07-19 | Viracta Subsidiary, Inc. | METHODS OF TREATMENT OF VIRAL ASSOCIATED CANCER WITH HISTONE DEACETYLASE INHIBITORS |
CN114829375A (zh) * | 2019-10-07 | 2022-07-29 | 维拉克塔附属公司 | 具有降低的副作用的hdac治疗的剂量 |
EP4069229A4 (en) * | 2019-12-05 | 2024-02-07 | Viracta Subsidiary, Inc. | SOLID STATE FORMS OF HDAC INHIBITOR |
CA3196385A1 (en) * | 2020-10-28 | 2022-05-05 | Xiaohu Deng | Hdac inhibitor solid state forms |
EP4355729A1 (en) | 2021-06-16 | 2024-04-24 | Celgene Corporation | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
CN115417877B (zh) * | 2022-09-20 | 2024-05-14 | 杭州师范大学 | 组蛋白去乙酰化酶抑制剂及其制备和在制备抗癌症药物上的应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60320957D1 (en) * | 2002-03-13 | 2008-06-26 | Janssen Pharmaceutica Nv | Sulfonylderivate als histone-deacetylase-inhibitoren |
ATE396971T1 (de) * | 2002-03-13 | 2008-06-15 | Janssen Pharmaceutica Nv | Sulfonylaminoderivate als neue inhibitoren von histondeacetylase |
WO2003075929A1 (en) | 2002-03-13 | 2003-09-18 | Janssen Pharmaceutica N.V. | Inhibitors of histone deacetylase |
US7247092B2 (en) | 2003-06-09 | 2007-07-24 | Igt | Gaming device having a multiplier poker game |
WO2005007091A2 (en) | 2003-07-07 | 2005-01-27 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
WO2005004861A1 (en) | 2003-07-15 | 2005-01-20 | Korea Research Institute Of Bioscience And Biotechnology | A use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same |
JP2007501775A (ja) | 2003-08-07 | 2007-02-01 | ノバルティス アクチエンゲゼルシャフト | 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤 |
PL1656348T4 (pl) | 2003-08-20 | 2007-07-31 | Pharmacyclics Inc | Pochodne acetylenu jako inhibitory deacetylazy histonowej |
ATE472534T1 (de) | 2003-09-22 | 2010-07-15 | S | Benzimidazolderivate: herstellung und pharmazeutische anwendungen |
CA2539117A1 (en) | 2003-09-24 | 2005-04-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
-
2005
- 2005-05-19 GB GBGB0510204.1A patent/GB0510204D0/en not_active Ceased
-
2006
- 2006-05-15 BR BRPI0611522-5A patent/BRPI0611522B1/pt active IP Right Grant
- 2006-05-15 AT AT06727119T patent/ATE494283T1/de active
- 2006-05-15 MX MX2007013066A patent/MX2007013066A/es active IP Right Grant
- 2006-05-15 ES ES06727119T patent/ES2358604T3/es active Active
- 2006-05-15 GB GB0618717A patent/GB2429707B/en not_active Expired - Fee Related
- 2006-05-15 EP EP06727119A patent/EP1881977B1/en not_active Not-in-force
- 2006-05-15 WO PCT/GB2006/001779 patent/WO2006123121A1/en active Application Filing
- 2006-05-15 JP JP2008511780A patent/JP4954200B2/ja active Active
- 2006-05-15 KR KR1020077023574A patent/KR20080016539A/ko not_active Application Discontinuation
- 2006-05-15 AU AU2006248788A patent/AU2006248788B2/en not_active Ceased
- 2006-05-15 NZ NZ562519A patent/NZ562519A/en unknown
- 2006-05-15 CN CN2006800136471A patent/CN101163696B/zh active Active
- 2006-05-15 PT PT06727119T patent/PT1881977E/pt unknown
- 2006-05-15 CA CA2605050A patent/CA2605050C/en active Active
- 2006-05-15 PL PL06727119T patent/PL1881977T3/pl unknown
- 2006-05-15 DE DE602006019410T patent/DE602006019410D1/de active Active
- 2006-05-15 US US11/918,237 patent/US7932246B2/en active Active
- 2006-05-15 DK DK06727119.7T patent/DK1881977T3/da active
-
2007
- 2007-10-07 IL IL186362A patent/IL186362A/en active IP Right Grant
- 2007-11-07 ZA ZA200709608A patent/ZA200709608B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CN101163696A (zh) | 2008-04-16 |
JP4954200B2 (ja) | 2012-06-13 |
CN101163696B (zh) | 2011-09-14 |
BRPI0611522B1 (pt) | 2021-08-03 |
BRPI0611522A2 (pt) | 2010-09-21 |
DK1881977T3 (da) | 2011-04-04 |
GB2429707B (en) | 2007-06-13 |
MX2007013066A (es) | 2008-01-11 |
CA2605050A1 (en) | 2006-11-23 |
DE602006019410D1 (de) | 2011-02-17 |
NZ562519A (en) | 2010-11-26 |
ATE494283T1 (de) | 2011-01-15 |
EP1881977B1 (en) | 2011-01-05 |
AU2006248788B2 (en) | 2011-05-26 |
IL186362A0 (en) | 2008-01-20 |
KR20080016539A (ko) | 2008-02-21 |
PT1881977E (pt) | 2011-04-11 |
AU2006248788A1 (en) | 2006-11-23 |
US7932246B2 (en) | 2011-04-26 |
WO2006123121A1 (en) | 2006-11-23 |
GB2429707A (en) | 2007-03-07 |
EP1881977A1 (en) | 2008-01-30 |
US20100152155A1 (en) | 2010-06-17 |
ES2358604T3 (es) | 2011-05-12 |
GB0618717D0 (en) | 2006-11-01 |
CA2605050C (en) | 2014-01-21 |
PL1881977T3 (pl) | 2011-07-29 |
GB0510204D0 (en) | 2005-06-22 |
IL186362A (en) | 2012-01-31 |
JP2008540623A (ja) | 2008-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL186362A0 (en) | Histone deacetylase inhibitors | |
MX2009004279A (es) | Hidroxamatos como inhibidores de histona desacetilasa. | |
NO20061157L (no) | 4-pyramidonderivater og deres anvendelse som peptidylpeptidmeinbibitorer | |
HK1125359A1 (en) | N-sulphonylpyrroles and their use as histone deacetylase inhibitors n- | |
NO20044557L (no) | Inhibitorer av histon deacetylase | |
ATE424395T1 (de) | Aminoderivate als histone-deacetylase-inhibitoren | |
IL164511A0 (en) | Heterocyclic compounds | |
MX2008002293A (es) | Uso novedoso de compuestos peptidicos para tratar dolor muscular. | |
DE60143520D1 (de) | Inhibitoren der histon-deacetylase | |
BRPI0510177B8 (pt) | composto, composição farmacêutica e uso do mesmo | |
TW200603823A (en) | Novel use of peptide compounds for treating essential tremor and other tremor syndromes | |
ATE439355T1 (de) | 2 aminocarbonyl-substituierte piperazin- oder diaza-cyclische verbindungen als apoptose-protein-inhibitor (iap)-modulatoren | |
ATE471740T1 (de) | Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer | |
TR200401793T4 (tr) | Perindopril tuzu ve bunu içeren farmasötik bileşimler. | |
MX2007003119A (es) | Nuevas amidas heterociclicas. | |
DE60112306D1 (de) | Kondensierte pyrazindionderivate als pde5 inhibitore | |
AR044452A1 (es) | Combinacion de un antagonista del receptor p2x7 y un inhibidor del factor de necrosis tumoral alfa | |
MXPA05009282A (es) | Derivados de anilina sustituidos. | |
TW200738244A (en) | 20-Alkyl, gemini vitamin D3 compounds and methods of use thereof | |
ATE325115T1 (de) | Pyrimidinderivate als selektive cox-2-inhibitoren | |
DK0984936T3 (da) | Cyanoguanidiner som celleproliferationsinhibitorer | |
ATE337320T1 (de) | Indolderivate als pde5-inhibitoren | |
EA200501557A1 (ru) | Новый способ синтеза (2s)-индолин-2-карбоновой кислоты и использование в синтезе периндоприла | |
DE60213798D1 (de) | Carbolinderivate als pdev inhibitoren | |
SG171472A1 (en) | Substituted aniline derivatives |